Pembrolizumab ImprovesProgression-FreeSurvival in Relapsed/Refractory Hodgkin Lymphoma

被引：3

作者：

不详

机构：

来源：

ONCOLOGIST | 2020年 / 25卷

关键词：

D O I：

10.1634/theoncologist.2020-0561

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the phase III KEYNOTE-204 trial, pembrolizumab significantly improved progression-free survival compared with brentuximab vedotin in patients with relapsed or refractory classic Hodgkin lymphoma (cHL), confirming pembrolizumab as the new standard of care in this setting.

引用

页码：S18 / S19

页数：2

共 3 条

[1] Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 [J].

Chen, Robert ;

Zinzani, Pier Luigi ;

Lee, Hun Ju ;

Armand, Philippe ;

Johnson, Nathalie A. ;

Brice, Pauline ;

Radford, John ;

Ribrag, Vincent ;

Molin, Daniel ;

Vassilakopoulos, Theodoros P. ;

Tomita, Akihiro ;

von Tresckow, Bastian ;

Shipp, Margaret A. ;

Lin, Jianxin ;

Kim, Eunhee ;

Nahar, Akash ;

Balakumaran, Arun ;

Moskowitz, Craig H. .

BLOOD, 2019, 134 (14) :1144-1153

[2] Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma [J].

Connors, J. M. ;

Jurczak, W. ;

Straus, D. J. ;

Ansell, S. M. ;

Kim, W. S. ;

Gallamini, A. ;

Younes, A. ;

Alekseev, S. ;

Illes, A. ;

Picardi, M. ;

Lech-Maranda, E. ;

Oki, Y. ;

Feldman, T. ;

Smolewski, P. ;

Savage, K. J. ;

Bartlett, N. L. ;

Walewski, J. ;

Chen, R. ;

Ramchandren, R. ;

Zinzani, P. L. ;

Cunningham, D. ;

Rosta, A. ;

Josephson, N. C. ;

Song, E. ;

Sachs, J. ;

Liu, R. ;

Jolin, H. A. ;

Huebner, D. ;

Radford, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04) :331-344

[3]

Kuruvilla J, 2020, 2020 AM SOC CLIN ONC, DOI 10.1200/JCO.2020.38.15_suppl.8005

← 1 →